EcoDrugPlus

Camp-Specific 3',5'-Cyclic Phosphodiesterase 4b-Like

Ensembl ID : ENSTRUG00000001133
Gene Symbol: LOC101077593
2 Cross references
224 Possible Orthologues:

Camp-Specific 3',5'-Cyclic Phosphodiesterase 4c-Like

Ensembl ID : ENSTRUG00000015440
Gene Symbol: LOC101075176
2 Cross references
195 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1c Subunit

Ensembl ID : ENSTRUG00000016197
Gene Symbol: CACNA1C
1 Cross references
213 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1s Subunit, A

Ensembl ID : ENSTRUG00000032387
Gene Symbol: CACNA1SA
1 Cross references
192 Possible Orthologues:

Calcium Channel, Voltage-Dependent, P/q Type, Alpha 1a Subunit, B

Ensembl ID : ENSTRUG00000007330
Gene Symbol: CACNA1AB
2 Cross references
192 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Alpha 2/delta Subunit 1a

Ensembl ID : ENSTRUG00000014542
Gene Symbol: CACNA2D1A
1 Cross references
226 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 7a

Ensembl ID : ENSTRUG00000006755
Gene Symbol: CACNG7A
2 Cross references
184 Possible Orthologues:

Calcium Sensing Receptor

Ensembl ID : ENSTRUG00000016870
Gene Symbol: CASR
3 Cross references
202 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 1

Ensembl ID : ENSTRUG00000013608
Gene Symbol: CACNA2D1
3 Cross references
226 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 2

Ensembl ID : ENSTRUG00000014312
Gene Symbol: CACNA2D2
3 Cross references
195 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 2

Ensembl ID : ENSTRUG00000012769
Gene Symbol: CACNA2D2
3 Cross references
209 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 3

Ensembl ID : ENSTRUG00000008741
Gene Symbol: CACNA2D3
3 Cross references
214 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).